Solana Analyst Price Targets - Benzinga

Solana Co

HSDTNASDAQ

Trade with Public

Trade with Public

$2.62

-0.24-8.39%

Últ. Act.: Oct 1, 4:08 AM

$2.66

-0.20-6.99%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

Solana Analyst Price Targets

Wall Street analyst price targets and consensus rating for Solana (HSDT).

Price Target Range — 3 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$6003Upside to Avg. PT+225564.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	B. Riley Securities	Fedor Shabalin	PT Raise	Buy	$4→$4
Sep 3, 2026	B. Riley Securities	Fedor Shabalin	PT Raise	Buy	$3→$4
Aug 17, 2026	B. Riley Securities	Fedor Shabalin	PT Cut	Buy	$3→$3
Apr 6, 2026	Maxim Group	Matthew Galinko	Assumes	Hold→Buy	$4
Oct 16, 2024	Maxim Group	Anthony Vendetti	Downgrade	Buy→Hold	—
Mar 5, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$5→$24

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Solana, Raises Price Target to $4

B. Riley Securities analyst Fedor Shabalin maintains Solana (NASDAQ:HSDT) with a Buy and raises the price target from $3.5 to $4.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Solana, Raises Price Target to $3.5

B. Riley Securities analyst Fedor Shabalin maintains Solana (NASDAQ:HSDT) with a Buy and raises the price target from $2.5 to $3.5.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Solana, Lowers Price Target to $2.5

B. Riley Securities analyst Fedor Shabalin maintains Solana (NASDAQ:HSDT) with a Buy and lowers the price target from $3 to $2.5.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Helius Medical Tech to Hold

Maxim Group analyst Anthony Vendetti downgrades Helius Medical Tech (NASDAQ:HSDT) from Buy to Hold.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Helius Medical Tech, Adjusts Price Target To $24

Roth MKM analyst Jonathan Aschoff maintains Helius Medical Tech (NASDAQ:HSDT) with a Buy, adjusts target to $24 from $5.

Benzinga Newsdesk

PRO
Hearing Roth Capital Partners Raises Helius Medical Technologies PT To $24

Benzinga Newsdesk